TrumpRx has signed deals with 86% of the branded drug market. But are prices actually falling for most Americans? A doctor takes a closer look at who benefits and what’s next.
Why fee-for-service and value-based care are failing, and why only a “moonshot” in healthcare payment models can make care affordable again.
Trump’s orders move the U.S. a few steps closer to more widespread research on and use of two sets of controversial yet promising drugs, psychedelic and cannabis products
Mark Cuban’s Cost Plus Drug Company and Humana’s CenterWell Pharmacy confirmed they have formed a partnership “to develop new end-to-end employer prescription solutions.”
Specialty drugs are an increasing worry for health plans and employers as new and innovative therapies enter the U.S. market and patients flock to them.
Since 2019, tennis participation in the U.S. has grown by 54 percent. The surge in tennis playing that started during the COVID-19 pandemic has persisted.
Over the last few decades, physicians are increasingly pursuing subspecialty training.
Excessive napping may indicate serious metabolic health issues.
AI‑designed intracellular antibody fragments can stay stable inside cells and bind misfolded proteins, opening new treatment routes for diseases.
Membership medicine is booming. Medicare’s new APCM codes, combined with technology-enabled care delivery partners, offer a path to scale concierge-style care beyond those who can afford it.